Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. Show more
Location: 22 Boston Wharf Road, Boston, MA, 02210, United States | Website: https://www.astriatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
359.5M
52 Wk Range
$3.56 - $12.92
Previous Close
$6.67
Open
$6.65
Volume
283,442
Day Range
$6.27 - $6.80
Enterprise Value
107.8M
Cash
295.1M
Avg Qtr Burn
-24.03M
Insider Ownership
0.49%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
navenibart (STAR-0215) Details Hereditary angioedema | Phase 3 Data readout | |
STAR-0215 Details Hereditary angioedema | Phase 1/2 Data readout | |
STAR-0310 Details Atopic dermatitis | Phase 1a Data readout |